Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.

Autor:	Alaklabi S; Department of Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.; Cancer Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia., Roy AM; Department of Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY., Zagami P; Department of Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC., Chakraborty A; Department of Medicine, Temple University, Philadelphia, PA., Held N; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI., Elijah J; Department of Pharmacology, Northeastern University School of Pharmacy and Pharmaceutical Sciences, Boston, PA., George A; Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY., Attwood K; Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY., Shaikh SS; Department of Medicine, Division of Hematology/Oncology, University of Texas Health San Antonio, San Antonio, TX., Chaudhary LN; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI., Abdou Y; Department of Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC., Gandhi S; Department of Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Jazyk:	angličtina
Zdroj:	JCO oncology practice [JCO Oncol Pract] 2024 Oct 01, pp. OP2400242. Date of Electronic Publication: 2024 Oct 01.
DOI:	10.1200/OP.24.00242
Abstrakt:	Purpose: Sacituzumab govitecan (SG) is approved for the treatment of metastatic triple-negative breast cancer (mTNBC). We report the real-world clinical effectiveness and toxicity data of SG in patients with mTNBC. Methods: A multi-institution retrospective study of patients with mTNBC treated with SG from January 2021 to May 2023 was conducted. Demographic and clinicopathologic variables were collected. Univariate and multivariate Cox regression models were used for survival analysis. Results: A total of 115 patients were included. The median age at SG initiation was 60 years (range, 31-85). All patients were female; 73 (63.5%) were White and 31 (27.0%) were Black. The median number of previous therapies in the metastatic setting was two (range, 0-8). Sixty-one (56.0%) patients had primary refractory disease. Median relative dose intensity was 92% (range, 33%-100%). Grade 3 or higher adverse events (AEs) were seen in 50.9% of patients, which included neutropenia (35.7%), anemia (27.0%), vomiting (16.5%), fatigue (8.7%), and diarrhea (7.0%). Dose reductions and treatment discontinuation due to AEs were required in 51.3% and 13.2%, respectively. The objective response rate (ORR) was 27.8%. Median overall survival was 9.6 months (95% CI, 7.8 to 12.9) and median progression-free survival (PFS) was 4.8 months (95% CI, 3.6 to 5.9). In patients with human epidermal growth factor receptor 2 (HER2)-low mTNBC who received trastuzumab deruxtecan (T-DXd) after SG, the ORR to T-DXd was 34.8% and median PFS was 7 months (95% CI, 4.6 to 10.1). Conclusion: In a real-world cohort of heavily pretreated patients with mTNBC, SG retains its clinical activity. In a subgroup with HER2-low disease, T-DXd continues to demonstrate promising clinical activity after SG, supporting the use of sequential antibody-drug conjugates in this population.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu